After-Hours Stock Movers:

Arbutus Biopharma Corporation (Nasdaq: ABUS) 55% HIGHER; reports positive follow-up data from a Phase 1a/1b clinical trial (AB-729-001) in chronic HBV subjects on nucleos(t)ide therapy who received a single subcutaneous injection of 60 mg of AB-729, a proprietary GalNAc delivered RNAi compound.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 14.7% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.

Gamida Cell Ltd. (Nasdaq: GMDA) 13% LOWER; announced the launch of a proposed follow-on public offering of its ordinary shares. In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares to be sold in the offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. All of the shares in the offering are to be sold by Gamida Cell.

Gossamer Bio, Inc. (Nasdaq: GOSS) 11.7% LOWER; announced that it intends to offer, subject to market and other conditions, shares of common stock and convertible senior notes due 2027 (the notes) in separate concurrent underwritten public offerings registered under the Securities Act of 1933, as amended.

Danaos (NYSE: DAC) 10.2% HIGHER; reported Q1 EPS of $1.34, $0.15 better than the analyst estimate of $1.19. Revenue for the quarter came in at $106.2 million versus the consensus estimate of $103.01 million.

Baidu.com (NASDAQ: BIDU) 9% HIGHER; reported Q1 EPS of $1.25, $0.68 better than the analyst estimate of $0.57. Revenue for the quarter came in at $3.18 billion versus the consensus estimate of $3.1 billion. Baidu.com sees Q2 2020 revenue of $3.5-3.9 billion, versus the consensus of $3.62 billion.

Clovis Oncology, Inc. (NASDAQ: CLVS) 7.5% LOWER; announced today that it has commenced an underwritten public offering of common stock. Clovis Oncology intends to offer, subject to market and other conditions, $85 million of shares of its common stock in an underwritten registered public offering. In connection with this offering, Clovis Oncology intends to grant to the underwriters a 30-day option to purchase up to an additional $12.75 million of shares of its common stock on the same terms and conditions. All shares of the common stock to be sold in the offering will be offered by Clovis Oncology.

Applied DNA Sciences (NASDAQ: APDN) 6% HIGHER; reported Q2 EPS of ($0.79), $0.02 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $552.47 thousand versus the consensus estimate of $950 thousand.

Moderna, Inc. (Nasdaq: MRNA) 3.2% LOWER; announced that it has commenced an underwritten public offering of $1.25 billion in shares of common stock. In addition, Moderna expects to grant the underwriters a 30-day option to purchase up to an additional $187.5 million in shares of common stock in connection with the public offering. All shares of common stock will be offered by Moderna.

Cornerstone Building Brands (NYSE: CNR) 3.1% HIGHER; CEO, James Metcalf, bought 100,000 shares on 05/15 at $4.42.

Atlas (NYSE: ATCO) 2.9% HIGHER; BMO Capital upgraded from Market Perform to Outperform with a price target of $9.00.

Rapt Therapeutics (NASDAQ: RAPT) 2.8% HIGHER; Cantor Fitzgerald with an Overweight rating and a price target of $37.00.